Drugs / 177Lu-EB-PSMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04996602 | Jan 2019 → Sep 2022 | prostate cancer | Peking Union Medical College Hospital | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-EB-PSMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04996602 ↗ |
| Route | Intravenous | “Patients were intravenous administrated with the dose about 2.0 GBq (55 mCi) of 177Lu-EB-PSMA every 8 weeks (±1 week) for a maximum of 3 cycles.” NCT04996602 ↗ |